Wall Street Analysts: 503A Peptide Drugs Still Have a Chance of Approval!

Needham analyst Ryan MacDonald stated that the suggestions previously put forward by FDA staff were "indeed somewhat unexpected," but this does not mean it will ultimately be rejected.

He said in the Hims investor community, "This is not the end of the story." He added that although the probability of approval may have slightly decreased at present, he still believes it will ultimately be approved.

MacDonald further explained: The FDA Advisory Committee still needs to review the relevant evidence; listen to the opinions of various stakeholders; and form a formal recommendation before the FDA makes its final decision.

He also pointed out: The final decision-making authority still lies with the FDA management, but the U.S. Department of Health and Human Services (HHS) is responsible for overseeing the FDA; and the U.S. Secretary of Health, Robert F. Kennedy Jr. (RFK Jr.), has been publicly supportive of relaxing (deregulating) policies related to peptide drugs.

In a nutshell: Needham's view is relatively optimistic: although the opinions previously given by FDA staff have increased uncertainty, the entire approval process is not over yet, and the final decision on approval still rests with the FDA management. The analyst still believes there is a high likelihood of the peptide drug ultimately being approved, just that the probability of success has slightly decreased compared to before.$Hims & Hers Health(HIMS.US) $Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)